Accunea is a point-of-care diagnostics company which is developing RenoSure, a miniature device for monitoring multiple biomarkers of organ function continuously and in real-time. This will enable close monitoring of kidney transplant patients both pre- and post-operatively to ensure every patient receives a kidney in the best possible condition, and recovers without complications. RenoSure is assisted by a proprietary artificial intelligence which enables early warnings from trend analysis, as well as enabling anonymised data aggregation and analytics for both individual and population-level health.